Roche targets more than $3 billion in annual obesity sales

Roche (ROG.S) said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics have the combined potential of more than 3 billion Swiss francs ($3.6 billion) in annual sales.